Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
Tue April 2, 2019 7:00 AM|Business Wire|About: VSTM
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 11:50 a.m. BST in London, UK.
A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20190402005118r1&sid=acqr7&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005118/en/
Verastem Oncology:
Rob Gagnon
Chief Financial Officer
+1 781-469-1681
rgagnon@verastem.com
Investors:
Joseph Rayne
Argot Partners
+1 617-340-6075
joseph@argotpartners.com
Source: Verastem, Inc.
Copyright Business Wire 2019
Sooner than later the companies tech will catch notice. Adding shares when I can get them reasonably still.
TG Therapeutics (TGTX) Presents At AACR Annual Meeting 2019 - Slideshow
https://seekingalpha.com/article/4252179-tg-therapeutics-tgtx-presents-aacr-annual-meeting-2019-slideshow
TG Therapeutics (TGTX) Presents At AACR Annual Meeting 2019
Apr 1, 2019
12:00 PM EDT
TG Therapeutics AACR 2019 Data Review Call
Listen to webcast
View Additional Information
Supporting Materials
View Presentation
http://ir.tgtherapeutics.com/events
Also have $TGTX in the clinical trials ETF $BBC that has 53,943 shares. Institutional ownership has been picking up within the last quarter, plus 3 phase 3 trials in a well tolerate effective drug/drugs combo.
This is why I hold a non-trading position now:
NOW ENROLLING THE PHASE 2b UNITY-NHL TRIAL: Ublituximab + TGR-1202 Compared to TGR-1202 in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)
THE PHASE 3 ULTIMATE I & II TRIALS (ONGOING, BUT NO LONGER RECRUITING): Ublituximab as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS); ULTIMATE I & ULTIMATE II
THE UNITY-CLL PHASE 3 TRIAL (ONGOING, BUT NO LONGER RECRUITING): Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients with Chronic Lymphocytic Leukemia (UNITY-CLL)
THE GENUINE PHASE 3 TRIAL (ONGOING, BUT NO LONGER RECRUITING): Ublituximab in Combination with Ibrutinib Versus Ibrutinib Alone in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
http://www.tgtherapeutics.com/clinical-trials/index.cfm
Not trading this one any more, holding a core of 14,500 shares because of what the company has in the pipeline. This stock has moved fast in the past 20% plus and i'm holding all my free shares to get the multibagger here.
This one is good for a trade but easy to lose out on better profits also. GLTY
Perfect gap fill now lets see if this is just a sell the news day.
Cantor Fitzgerald is low balling the PT for now, but i`m good with it......
“. We are initiating coverage of TG Overweight rating and $17 12-month price target. We believe umbralisib (PI3K inhibitor) and ublituximab (anti-CD20) have attractive profiles in oncology and autoimmune B-cell diseases. We view both lead assets as clinically de-risked with proven targets, but we think investors are cautious on the PI3K commercial potential and give no credit to multiple sclerosis (MS) due to the competitive yet price sensitive landscape. Our thesis is that next-generation assets with a differentiated profile can gain share in late-stage lymphoma and that competing on price in MS with a similar drug can drive share.”,” Cantor Fitzgerald’s analyst wrote.
Find it funny that there are sellers after hours as Mon. could have some top line data revealed. I know sell the news but they have not even release any, novice traders I guess.
TG Therapeutics conference call April 1 on umbralisib in marginal zone lymphoma
Mar. 29, 2019 4:14 PM ET|About: TG Therapeutics, Inc. (TGTX)|By: Douglas W. House, SA News Editor
TG Therapeutics (NASDAQ:TGTX) will host a conference call on Monday, April 1, at 12:00 pm ET to discuss interim data from a Phase 2b clinical trial, UNITY-NHL, evaluating umbralisib in patients with marginal zone lymphoma (MZL), a type of slow-growing non-Hodgkin lymphoma, who have received at least one prior anti-CD20 regimen.
In February, the company announced that the MZL cohort met the primary endpoint of objective response rate (ORR). The final analysis will be completed later this year after all participants have received at least nine cycles of follow-up.
Shares are up 1% after hours.
https://seekingalpha.com/news/3447018-tg-therapeutics-conference-call-april-1-umbralisib-marginal-zone-lymphoma
Yes it was.
I`ve had this for years and have been adding all along. I added last year when I believed the selloff was overdone on 07/12/2018 1,500.0000 $13.15 and i`ve laddered all the way down as $TGTX has a remarkable pipeline.
Thought you were looking at $7.99 to add? No matter you have a good basis. GL
Yep and this should even look better end of 1st quarter.
Institutional investors purchased a net $6.9 million shares of TGTX during the quarter ended December 2018, and now own 68.67% of the total float, a percentage that is typical for companies in the Biotechnology industry.
https://money.cnn.com/quote/shareholders/shareholders.html?symb=TGTX&subView=institutional
The news just keeps on coming:
Pressure BioSciences Looks to Disrupt the Life Sciences Sector with Its Novel Technologies
https://seekingalpha.com/pr/17459905-pressure-biosciences-looks-disrupt-life-sciences-sector-novel-technologies
TG-1101 and TGR-1202 - UNITY-NHL study. Data presentation at AACR April 1, 2019; 3pm.
It very well could make a strong move with it`s upcoming data too.
It may come in some from this move as it filled a gap made back in late Sept. of 2018. I hope it consolidates or better yet continues this move up. Ether way this is undervalued with all the ongoing trials and data yet to be released. GLTY
Interesting Friday and well deserved.........
Cantor Fitzgerald initiates coverage with overweight rating and $17 PT
TG Therapeutics call volume above normal and directionally bullish Bullish option flow detected in TG Therapeutics with 6,989 calls trading, 9x expected, and implied vol increasing almost 22 points to 95.20%. Apr-19 10 calls and Apr-19 6 puts are the most active options, with total volume in those strikes near 6,400 contracts. The Put/Call Ratio is 0.46. Earnings are expected on May 9th.
Nothing new except a few more open trails added since reporting.
Right now it's an easy short play due to Verastem`s 50/50 change it makes or does not make good sales of COPIKTRA so the algo`s will continue their scalping 1/10th of a cent on there trades bringing the price down until numbers and trials have a clearer outlook.
For now it's accumulate and wait out the games as the new trials alone have more value than what the stocks trading at current.
https://clinicaltrials.gov/ct2/results?cond=&term=Duvelisib+&cntry=&state=&city=&dist=
Looking like the share price may of bottomed out seeing some reasonable accumulation now.
Today's volume of 8,930 shares is on pace to be much greater than PBIO's 10-day average volume of 10,666 shares.
Pixelworks: Mobile Gaining Traction - 85% Upside
https://seekingalpha.com/article/4251264-pixelworks-mobile-gaining-traction-85-percent-upside
Multi-million dollar product, we needs some licence fees.
Verastem Cancer Therapy Should Get Traction, Raise Stock Price
https://seekingalpha.com/article/4250644-verastem-cancer-therapy-get-traction-raise-stock-price
In this preview of CNBC's Jim Cramer exclusive interview with CVS Health CEO Larry Merlo, the two discuss the company's decision to offer CBD products in stores in 8 states.
https://www.cnbc.com/video/2019/03/21/cvs-ceo-explains-why-the-company-decided-to-sell-cbd-products-in-select-stores.html?&qsearchterm=cvs%20ceo
I sold during the hugh gap up 03/2019 after I started buying shares back in mid July 2018. I think it needs some consolidation in here before another upterend. Trump still playing the Tweet card on trade makes this one hard to hold but still have a strong position in emerging markets stock/bonds as i'm buying the dips and holding there.
From what i'm used to an analyst uses a 12 month time frame unless otherwise stated.
Follow the money the seasonality cycle for Healthcare is coming into the strongest positive period for the year. Expecting an update from management about their progression to introduce their sheer technology to marijuana companies/industry.
I believe $PBIO is a perfect buyout or licence candidate from any of the larger MJ players that want the technology in their CBD products.
The UST Platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.
Both analyst have lowered their price targets for now but I see them raising likely again as sales progress and ongoing trials start proving out going forward.
Verastem analyst commentary at H.C. Wainwright Verastem price target lowered to $10 from $13 at H.C. Wainwright. H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Verastem to $10 from $13 saying that while the Copiktra launch progressing, the early ramp is slower than expected. The analyst, however, continues to believe in the long-term potential of Copiktra and reiterates a Buy rating on the shares.
Verastem Is Maintained at Outperform by Raymond James
March 14, 2019 Verastem Is Maintained at Outperform by Raymond James
DJ Verastem Price Target Cut to $6.00/Share From $12.00 by Raymond James
Support for Cannabis Legalization Ramps up With Increasing Prevalence of CBD Products
9:00 am ET March 11, 2019
Medical cannabis has been a controversial subject of matter among various national governments and healthcare facilities around the world. The big debate over the plant centers around its safety, its decriminalized status, its addictive properties and if it's even effective. While multiple studies have set out to learn more about cannabis and its components, some researchers have already validated it. Now, consumers are primarily using cannabis to treat medical conditions such as chronic pain, cancer, seizures, and even muscle spasms. Medical cannabis is also increasingly being adopted by medical facilities as an alternative to traditional drugs such as opioids, which often pose high side effect risks. As of now, studies have suggested that cannabis is not addictive when compared to opioids and requires a much smaller dosage while providing similarly effective results. Advancements in clinical trials will also further accelerate the growth of the medical cannabis sector, as more positive results flow in and countries begin to adopt medical cannabis as a registered treatment for certain maladies. According to data compiled by Global Market Insights, the U.S. medical marijuana market was valued at USD 7.0 Billion in 2017 and is expected to witness a CAGR of more than 36% from 2018 to 2024. Pressure BioSciences, Inc. (OTC: PBIO), CannTrust Holdings Inc. (NYSE: CTST) (TSX: TRST), Arcadia Biosciences, Inc. (NASDAQ: RKDA), Green Organic Dutchman Holdings Ltd. (OTC: TGODF) (TSX: TGOD), Curaleaf Holdings, Inc. (OTC: CURLF) (CSE: CURA)
While the U.S. cannabis marketplace accounts for the largest share in the world, other emerging countries are also doing their part in propelling the industry growth. Countries such as Germany, Italy, Mexico, Switzerland, and the United Kingdom have all legalized cannabis on a medical level in the past. According to ArcView Research, in partnership with BDS Analytics, regions like Australia are expected to account for USD 1.2 Billion worth of legal cannabis spending by 2027, while Germany is projected to drive in sales of USD 3.1 Billion. Even though cannabis is linked to having effective and efficient results in the medical aspect, the concern over its psychoactive effects still remains. Due to the various regulatory laws that pertain to cannabis, certain nations are implementing more lenient CBD, or cannabidiol, laws. CBD is much less controversial due to its non-psychoactive effects. And despite the major chemical difference between CBD and marijuana, CBD still offers consumers a beneficial therapeutic effect. "Least controversial is the extract from the hemp plant known as CBD (which stands for cannabidiol) because this component of marijuana has little, if any, intoxicating properties. CBD-dominant strains have little or no THC, so patients report very little if any alteration in consciousness," said Peter Grinspoon, M.D., a physician in Boston and Massachusetts General Hospital, "Many patients find themselves in the situation of wanting to learn more about medical marijuana, but feel embarrassed to bring this up with their doctor. My advice for doctors is that whether you are pro, neutral, or against medical marijuana, patients are embracing it, and although we don't have rigorous studies and "gold standard" proof of the benefits and risks of medical marijuana, we need to learn about it, be open-minded, and above all, be non-judgmental."
Pressure BioSciences, Inc. (OTCQB: PBIO) announced earlier last month that, "analytical testing on hemp-derived CBD oil processed via PBI's Ultra Shear Technology(TM) (UST(TM)) platform has confirmed that UST processing uniquely achieves the challenging criteria for creating highly-effective "nanoemulsions" of CBD oil in water, without loss or modification of CBD throughout the entire UST process (> 99% recovery).
The ultimate goal in mixing oil-based nutritional and therapeutic products like CBD oil into water, for effective oral or topical delivery and absorption, is to reduce the size of the oil drops to such a level that they seemingly 'vanish' into the water (become "water soluble"). These exceedingly small, nanometer-scale droplets are so tiny that it becomes very easy for the human (or other animal) body to absorb the oil-based nutrients or drugs (like CBD) directly from the inner surface of the oil droplet. Traditional processing methods struggle mightily with this challenge, but PBI's proprietary UST platform uses ultra-high pressure to create extreme shearing forces to make nanometer-scale droplets of fluids that become highly-stable, homogenized "nanoemulsions" of materials that normally do not mix (e.g., CBD oil and water).
Dr. Vera Gross, Director of Applications Development at PBI, explained: 'We asked an independent, university-affiliated laboratory to determine the size of oil droplets achieved in UST-processed CBD oil, using a universally-accepted sizing method called DLS. Their analytical results revealed that the UST- processed oil drops were reduced to approximately 65 nm in size, well into the 20-200 nm range targeted for truly effective nanoemulsion delivery and absorption of nutrients and therapeutics, such as CBD (Nano- and Microscale Drug Delivery Systems, 2017).'
Dr. Gross continued: 'It was critically important to also demonstrate that CBD from hemp-derived CBD oil was not lost or modified during UST processing. For this we enlisted the help of scientists at NutraFuels, Inc. (OTCQB: NTFU), which has an FDA-inspected, highly-qualified analytical testing laboratory with state-of-the-art equipment and well-trained chemists with years of experience in laboratory testing.'
Mr. Cooper Dodd, R&D Scientist at NTFU, said: 'Using a powerful laboratory method called HPLC to measure the concentrations of CBD and potential impurities, we determined that no appreciable amount of CBD was lost during the UST process. These results compare well to our standard processing method of ultrasonication, which can carry a risk of measurable loss of CBD, and sometimes creates the appearance of impurities if not performed properly. While there is more work to be done, as a nutraceutical manufacturer with products already on the market, we see these results as a robust leap towards better optimization of our CBD-enhanced products.'
Dr. Keith Warriner, Professor of Food Science at the University of Guelph (Toronto), and a recognized expert in the cannabis industry, commented: 'The data released today on UST-generated nanoemulsions of CBD oil are very impressive. Creating nanoemulsions of CBD oil with full preservation of CBD throughout the process, while not generating impurities, remains a significant challenge in the industry. These data indicate that UST can achieve that goal, thereby offering great promise to the future.'
Professor Warriner continued: 'Not only does the UST process appear capable of achieving stability of emulsions, but the controlled heating that also occurs may offer a valid alternative to thermal and non-thermal pasteurization methods to reduce the risk of harmful microbes in products such as edibles and topicals. I believe that CBD-infused topicals and similar products will prove more popular with users than edibles. However, to be successful, it is imperative that topicals be highly stable, safe, bioavailable, and readily absorbent nanoemulsions. After consideration of the data released today, the UST process appears to be a leading candidate to fill that important need.'
Dr. Bradford A. Young, Chief Commercial Officer of PBI, summarized: 'We were delighted to release a short video last week showing the ability of our new UST platform to make visually clear and stable mixtures of CBD oil and water. The scientific data released today have further validated the achievement of creating high quality, nanoemulsion mixtures of oil and water using our UST platform. In particular, these data specifically show that CBD levels are preserved all the way through UST processing to the finished product. We are very excited by these results and believe our proprietary Ultra Shear Technology can help a diverse variety of customers to develop a vast array of new and beneficial products spanning multiple large markets, including CBD and nutraceuticals, cosmetics and topicals, food and beverages, drug delivery and more.'"
After Developing A Revolutionary New Nanoemulsion Technology For CBD Oil, Pressure BioSciences Is Worth Watching Mar. 11, 2019
https://seekingalpha.com/article/4247839-developing-revolutionary-new-nanoemulsion-technology-cbd-oil-pressure-biosciences-worth
Ignore China's Steep Yield Curve And Start Preparing For QE - Here's Why
https://seekingalpha.com/article/4247603-ignore-chinas-steep-yield-curve-start-preparing-qe
Positioning Your Portfolio For A Slowing Economy
https://seekingalpha.com/article/4247301-positioning-portfolio-slowing-economy
The Chinese Exports Plunge Is Misleading
https://seekingalpha.com/article/4247338-chinese-exports-plunge-misleading
Biotech Is Worth The Hype, But Do You Have The Data?
https://seekingalpha.com/article/4245949-biotech-worth-hype-data